Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Vascular access (VA), optimally a subcutaneous arteriovenous fistula (AVF), is essential for hemodialysis. However, intraoperative vascular spasm during AVF creation can lead to early occlusion. While traditional agents like heparin or papaverine are sometimes administered, clear evidence supporting their practice is lacking. Fasudil hydrochloride, a Rho kinase inhibitor, effectively prevents arterial spasm in other vascular procedures, but its efficacy and safety for vasospasm prevention during the complex arterial-venous anastomosis of AVF creation remain unproven.
We conducted a single-group, open-label pilot study from March 2024 to March 2025 (N=10) with historical controls (N=55) treated between January 2023 and March 2025. The intervention group received 30mg of fasudil hydrochloride intravenously just prior to the arteriovenous anastomosis. Primary endpoints were the incidence of hypotension and hemorrhagic complications during the procedure and the early postoperative period. Secondary endpoints included initial patency, maturation, primary patency, brachial artery blood flow (Q), and access circuit thrombosis. To adjust for baseline imbalances, Propensity Score Matching (PSM) was performed using age, sex, and major baseline confounders with 1:1 nearest neighbor matching (caliper=0.2). Primary endpoints were reported descriptively. Secondary endpoints were compared in the PSM-matched samples using Wilcoxon Signed-Rank Test. This study was approved by the Institutional Ethics Committee (Approval No. CRB3180024) and registered with the Japan Registry of Clinical Trials (jRCT; registration number: jRCTs031220704).
The fasudil hydrochloride group (N=10) consisted of 8 males, with a median age of 73.5 years (interquartile range (IQR) : 58.75–77.00). The initial success rate was 100%, and no adverse events (hypotension or hemorrhage) were observed during the procedure and the early postoperative period. Ten successful 1:1 matched pairs were obtained for the comparative analysis. The historical control group (N=55) comprised 40 males, with a median age of 73.0 years (IQR: 61.0–81.0). Post-PSM analysis of the matched pairs revealed significantly higher QPOD1 and QPOD7 in the fasudil hydrochloride group (P < 0.05 for both).
The low incidence of adverse events following fasudil hydrochloride administration suggests its short-term safety and tolerability in AVF creation. The significantly improved postoperative Q preliminarily suggests efficacy in preventing intraoperative vasospasm during AVF creation. These findings strongly support proceeding to a large-scale Randomized Controlled Trial to verify the definitive efficacy and long-term outcomes of the use of fasudil hydrochloride.
